mTOR Inhibitors Market
- 2026 年市場規模
- USD 6.6 Bn
- 2033 年預估規模
- USD 8.3 Bn
- 年複合成長率 CAGR
- 5.8%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
mTOR Inhibitors Market, By Drug Type (Everomilus, Temsirolimus, Siromilus), By Indication (Oncology, Immunosuppressant, Organ Transplant, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Mammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus. Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.
Market Dynamics
Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period. For instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.
Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.
Key features of the study
• This report provides an in-depth analysis of global mTOR inhibitors market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global mTOR inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global mTOR inhibitors market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mTOR inhibitors
Market Segmentation
• By Drug Type
o Everomilus
o Temsirolimus
o Siromilus
• By Indication
o Oncology
o Immunosuppressant
o Organ Transplant
o Others
• By Route of Administration
o Oral
o Intravenous
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Regional Insights
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Novartis AG
o Hikma Pharmaceuticals PLC.
o Par Pharmaceutical
o Teva Pharmaceutical Industries Ltd.
o Reddy’s Laboratories Ltd.
o Zydus Cadilla
o Pfizer, Inc.
o Biocon
o Alkem Laboratories Ltd.
o Accord Healthcare Inc.
o Gland Pharma Ltd.
o Apotex Inc.
o Glenmark Pharmaceuticals Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Indication
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Key Development
o PEST Analysis
o Regulatory Scenario
o Pipeline Analysis
o New Product Launch/ Approval
o Epidemiology
o Market Trends
4. Global mTOR Inhibitors Market, By Drug Type, 2026-2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Everolimus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Temsirolimus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Sirolimus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global mTOR Inhibitors Market, By Indication, 2026-2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Oncology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Immunosuppressant
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Organ Transplantation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global mTOR Inhibitors Market, By Route of Administration, 2026-2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global mTOR Inhibitors Market, By Distribution Channel, 2026 - 2033 (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021-2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033 (USD Bn)
8. Global mTOR Inhibitors Market, By Region, 2026 - 2033 (USD Bn)
o Introduction
Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2021-2033
Regional Trends
o North America
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o U.S.
o Canada
o Latin America
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Market Size and Forecast, By Drug, 2021-2033 (USD Mn)
Market Size and Forecast, By Indication, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country/Region, 2021-2033 (USD Mn)
o South Africa
o Central Africa
o North Africa
9. Competitive Landscape
o Company Profiles
Novartis AG
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Hikma Pharmaceuticals PLC.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Par Pharmaceutical
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Reddy’s Laboratories Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Zydus Cadilla
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Pfizer, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Biocon
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Alkem Laboratories Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Accord Healthcare Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Gland Pharma Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Apotex Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Glenmark Pharmaceuticals Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們